The Global Biosimilar Monoclonal Antibodies market size was accounted at USD 4.98 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 25% from 2022 to 2030. Biosimilars are biological drugs, and they are large, complex biological molecules produced from living organisms that are often difficult to characterize and therefore difficult to copy. Monoclonal antibody biosimilars play a vital role in treating various chronic and autoimmune diseases. They also represent an opportunity to increase access and reduce costs for patients and healthcare systems.
Global Biosimilar Monoclonal Antibodies market growth is attributed to numerous factors such as biosimilar monoclonal antibodies market include the increasing patent expiries of mAbs, innovation of advanced mAbs, the growing number of biosimilars for oncology treatments, rising demand for lower-priced, cost-efficient biosimilar monoclonal antibodies, growing chronic and autoimmune diseases like cancer, rheumatoid arthritis, diabetes, and the rising older population. Moreover, increasing R&D investments for biological drugs are anticipated to fuel market adoption during the forecast period. Growing R&D activities result in innovative drug products, developmental procedures, and healthcare facilities, thereby boosting market growth.
However, the high cost of development processes, complex mAb manufacturing procedures, region-specific government rules regarding the production and use of biosimilars, lack of scientific standards for biosimilars are expected to hamper the market's growth in the coming years.
The Biosimilar Monoclonal Antibodies Market is segmented based on product, indication, and region. By product, the market comprises the infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products. The infliximab and rituximab segments are projected to hold the highest market share over the forecast period owing to their increasing use in treating various chronic and autoimmune diseases. The market is classified into oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications based on the indication. Among all, The oncology segment is predictable to dominate the market in the coming years due to the surge in biosimilar mAbs approvals for cancer treatments. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America region dominated this market in 2020 and is expected to continue its trend over the forecast period on account of the favourable reimbursement policies, increasing patent expiration, and the growing rate of biosimilar mAbs approvals.
Some of the key players operating in the biosimilar monoclonal antibodies market are BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.